Back to top
more

AbbVie (ABBV)

(Real Time Quote from BATS)

$201.28 USD

201.28
1,008,049

+0.81 (0.40%)

Updated Nov 5, 2024 11:46 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Simple Secrets Anyone Can Use to Reach Early Retirement - March 06, 2020

by Zacks Equity Research

Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.

AbbVie (ABBV) Stock Moves -1.21%: What You Should Know

by Zacks Equity Research

AbbVie (ABBV) closed the most recent trading day at $90.64, moving -1.21% from the previous trading session.

Alnylam, Vir Collaborate on RNAi Therapy for Coronavirus

by Zacks Equity Research

Alnylam (ALNY) expands its collaboration pact with Vir Biotechnology to develop RNAi therapeutics targeting SARS-CoV-2, the virus that induces Covid-19. Stock gains.

Inovio Surges on Expedited Timeline for Coronavirus Vaccine

by Zacks Equity Research

Inovio (INO) to initiate human clinical studies on INO-4800, its DNA vaccine, this April, for the treatment of the deadly coronavirus. The stock price shoots up.

Pfizer Plans Coronavirus Therapy, Progresses With Tanezumab BLA

by Zacks Equity Research

Pfizer (PFE) identifies potential antiviral compounds to develop a treatment for coronavirus disease. The FDA accepts regulatory application seeking approval for tanezumab for osteoarthritis.

Why You Shouldn't Bet Against AbbVie (ABBV) Stock

by Zacks Equity Research

AbbVie (ABBV) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

AbbVie's Venclexta Combo Fails in Late-Stage Leukemia Study

by Zacks Equity Research

AbbVie's (ABBV) blood cancer drug, Venclexta, in combination with chemotherapy fails to achieve statistically significant improvement in overall survival in treatment-naive AML patients.

AbbVie (ABBV) Gains As Market Dips: What You Should Know

by Zacks Equity Research

AbbVie (ABBV) closed the most recent trading day at $85.62, moving +0.23% from the previous trading session.

How Trading Your Own Retirement Can Fleece Your Financial Future - February 28, 2020

by Zacks Equity Research

From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.

Easy Investing Secrets to an Early Retirement - February 27, 2020

by Zacks Equity Research

Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.

Zacks Value Trader Highlights: AbbVie, Allergan, Occidental, Chevron and CVS

by Zacks Equity Research

Zacks Value Trader Highlights: AbbVie, Allergan, Occidental, Chevron and CVS

Tracey Ryniec headshot

One of Your Stock Investments is Being Acquired: Now What?

by Tracey Ryniec

One of your companies gets a buyout offer and the shares soar. There might be different strategies for traders and investors on what to do next.

Signs That Your Trading Will Ruin Your Retirement - February 20, 2020

by Zacks Equity Research

Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.

Easy Investing Secrets to an Early Retirement - February 19, 2020

by Zacks Equity Research

Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.

ImmunoGen (IMGN) Q4 Earnings & Sales Beat, Shares Rally

by Zacks Equity Research

ImmunoGen (IMGN) reports fourth-quarter results with earnings and revenues beating estimates.

The Keys to Successfully Timing the Markets - February 14, 2020

by Zacks Equity Research

Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?

Kinjel Shah headshot

Pharma Stock Roundup: ABBV, AGN Post Q4 Results, Another Alzheimer's Study Fails

by Kinjel Shah

AbbVie (ABBV) and Allergan (AGN) announce Q4 results.

The Zacks Analyst Blog Highlights: AbbVie, Accenture, TOTAL, Amazon.com and Intuit

by Zacks Equity Research

The Zacks Analyst Blog Highlights: AbbVie, Accenture, TOTAL, Amazon.com and Intuit

How Trading Your Own Retirement Can Fleece Your Financial Future - February 11, 2020

by Zacks Equity Research

Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.

Sheraz Mian headshot

Top Stock Research Reports for AbbVie, Accenture, TOTAL & Others

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including AbbVie (ABBV), Accenture (ACN) and TOTAL (TOT).

Kinjel Shah headshot

Allergan (AGN) Surpasses Q4 Earnings and Sales Estimates

by Kinjel Shah

Botox, Juvederm fillers and Vraylar drive Allergan's (AGN) fourth-quarter sales, making up for loss of exclusivity on some brands and lower sales of eye drug, Restasis.

Easy Investing Secrets to an Early Retirement - February 10, 2020

by Zacks Equity Research

Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.

AbbVie's (ABBV) Q4 Earnings Beat, 2020 View Solid, Stock Up

by Zacks Equity Research

AbbVie (ABBV) beat on earnings in the fourth quarter of 2019 while revenues meet the same. Shares up in pre-market trading following a solid 2020 outlook.

Kinjel Shah headshot

Pharma Stock Roundup: BMY, GSK, SNY Q4 Results, MRK Earnings & Split

by Kinjel Shah

Merck (MRK), Bristol Myers (BMY), Sanofi (SNY), Glaxo (GSK) and Novo Nordisk (NVO) announce Q4 results.

AbbVie (ABBV) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

AbbVie (ABBV) delivered earnings and revenue surprises of 0.45% and 0.03%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?